Document Detail


Abatacept.
MedLine Citation:
PMID:  16541185     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
New therapies, in particular the tumor necrosis factor-alpha-blocking drugs, have led to improved control of inflammation in rheumatoid arthritis for a proportion of patients. There remains a need for therapies for patients who do not respond to these drugs or in whom they are contraindicated or not tolerated. There is evidence that T cells are involved in the initiation and perpetuation of rheumatoid arthritis. Abatacept is the first in a new class of drugs targeted at T-cell function in autoimmune disease: the costimulation blockers. It has shown safety and efficacy in rheumatoid arthritis. Further trials of this and other costimulation blockers are in progress in rheumatoid arthritis and other diseases.
Authors:
Edward M Vital; Paul Emery
Related Documents :
8609945 - Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychl...
15051215 - Methotrexate therapy for ocular cicatricial pemphigoid.
18798705 - Donepezil: potential neuroprotective and disease-modifying effects.
19007425 - Abatacept in the treatment of rheumatoid arthritis.
12583825 - Tubulin interacting agents: novel taxanes and epothilones.
992875 - Inhibition of human neutrophil chemotaxis in vitro by phenothiazines and related compou...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  42     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-03-16     Completed Date:  2006-05-12     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  87-93     Citation Subset:  IM    
Affiliation:
Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Leeds, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antirheumatic Agents* / adverse effects,  pharmacology,  therapeutic use
Arthritis, Rheumatoid / drug therapy*,  immunology
Clinical Trials as Topic
Humans
Immunoconjugates* / adverse effects,  pharmacology,  therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*,  immunology
Chemical
Reg. No./Substance:
0/Antirheumatic Agents; 0/Immunoconjugates; 0/Tumor Necrosis Factor-alpha; 7D0YB67S97/abatacept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dronedarone: a new antiarrhythmic agent.
Next Document:  Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.